FDA Accelerates Drug Approvals with New Priority Voucher Program
The U.S. Food and Drug Administration (FDA) announced nine voucher recipients under the new Commissioner’s National Priority Voucher (CNPV) pilot program.
The program aims to accelerate approvals for companies aligned with “critical U.S. national health priorities.”
Each recipient has a product with significant potential to address a major national priority, such as meeting a large unmet medical need, reducing downstream healthcare utilization, addressing a public health crisis, boosting domestic manufacturing, or increasing medication affordability with Most Favored Nation pricing.
The FDA introduced the CNPV pilot program in June to expedite review processes for high-priority medications.
Author's summary: FDA introduces new voucher program.